4
Changes in Ownership
BIOMARIN PHARMACEUTICAL INC Filed Acc 0001048477-24-000002
Director sold 20,000 shares at an average $97.29 ($1,945,700)
- Director acquired 20,000 shares (option exercise)
- Director acquired 50 shares (code L)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES Director | 2024-01-08 | Other acquisition 10b5-1 | +50 | $99.05 | $4,953 | 425,162 | D: show line 1 in the form |
| BIENAIME JEAN JACQUES Director | 2024-01-09 | Option exercise 10b5-1 | +10,000 | $63.10 | $631,000 | 435,162 | D: show line 2 in the form |
| BIENAIME JEAN JACQUES Director | 2024-01-09 | Sale 10b5-1 | −10,000 | $98.19 | $981,900 | 425,162 | D: show line 3 in the form |
| BIENAIME JEAN JACQUES Director | 2024-01-10 | Option exercise 10b5-1 | +10,000 | $63.10 | $631,000 | 435,162 | D: show line 4 in the form |
| BIENAIME JEAN JACQUES Director | 2024-01-10 | Sale 10b5-1 | −10,000 | $96.38 | $963,800 | 425,162 | D: show line 5 in the form |
| Open-market sales · 20,000 sh · avg $97.29 · $1,945,700 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES Director | 2024-01-09 | Option exercise · Stock Option (Right to Buy Common Stock) 10b5-1 | −10,000 | 171,000 | D: show line 6 in the form | |||||
| BIENAIME JEAN JACQUES Director | 2024-01-10 | Option exercise · Stock Option (Right to Buy Common Stock) 10b5-1 | −10,000 | 161,000 | D: show line 7 in the form |
Loading xslF345X05/wk-form4_1705002030.xml…